Fluzone PF Pediatric Quadrivalent 2021-2022 was administered by a healthcare professional. Proper preparation and injection technique were essential for its safe and effective delivery.

• Preparation: The vaccine was supplied as a clear and slightly opalescent suspension for injection in a prefilled syringe or multi-dose vial. Before administration, the syringe or vial should have been visually inspected for particulate matter or discoloration. If any defects were present, the vaccine should not have been administered. The syringe or vial was gently shaken before use.
• Administration Route: The vaccine was administered intramuscularly. Intravenous administration was contraindicated.
• Single-Dose or Multi-Dose Presentation: The vaccine was available in 0.25 mL and 0.5 mL presentations, typically in prefilled single-dose syringes or multi-dose vials. Each dose was carefully measured according to the child’s age.
• Annual Vaccination: An annual flu vaccination was recommended because influenza viruses constantly evolve, and vaccine formulations are updated each year to match the predicted circulating strains.
• Post-Vaccination Monitoring: As with all injections, recipients were often advised to remain at the vaccination site for 15 minutes after administration to monitor for immediate allergic reactions or vasovagal syncope (fainting).
• Storage: The vaccine needed to be stored refrigerated between 2° to 8°C (35° to 46°F) and should not have been frozen, as freezing could denature the antigens and render the vaccine ineffective.

Fluzone PF Pediatric Quadrivalent 2021-2022 works by stimulating the body’s immune system to produce protective antibodies against the influenza viruses contained in the vaccine.

• Antigen Presentation: The vaccine contained inactive (killed) influenza virus components, specifically the hemagglutinin (HA) protein, from four different strains. When injected into the muscle, these antigens are recognized by the body as foreign.
• Immune System Activation: The immune system’s cells (like B-cells and T-cells) identify these antigens. B-cells are stimulated to produce antibodies that specifically target the influenza viruses. T-cells also become activated, helping to mount a cellular immune response.
• Antibody Production: It takes approximately two weeks after vaccination for the body to develop sufficient protective antibodies. These antibodies circulate in the bloodstream, ready to recognize and neutralize the actual influenza virus if the vaccinated child is exposed.
• Prevention of Infection/Severity: If exposed to one of the vaccine strains, the pre-existing antibodies can prevent infection or significantly reduce the severity of the illness, thus lowering the risk of complications.
• Quadrivalent Design: By including two influenza A strains and two influenza B strains, the vaccine provided broader protection against the influenza viruses most likely to circulate during the 2021-2022 flu season.

While Fluzone PF Pediatric Quadrivalent 2021-2022 was generally well-tolerated, like all vaccines, it could cause side effects. Most were mild and temporary. Serious side effects were rare.

• Common Local Side Effects (at injection site):
  • Pain, tenderness, redness (erythema), swelling, or a hardened lump (induration). These were usually mild to moderate and resolved within a few days.
  • Bruising.
• Common Systemic Side Effects (more frequent in younger children):
  • Fever (more common in infants and young children).
  • Irritability, fussiness, or crying (in infants and young children).
  • Drowsiness.
  • Loss of appetite.
  • Muscle aches (myalgia).
  • Headache.
  • Fatigue.
  • Nausea, vomiting, or diarrhea.
  • Soreness or swelling of lymph nodes.
• Serious Side Effects (Rare):
  • Severe Allergic Reaction (Anaphylaxis): This is rare but can occur within minutes to hours of vaccination. Symptoms include hives, swelling of the face/throat, difficulty breathing, dizziness, or weakness. Medical supervision is crucial during and immediately after vaccination to manage such reactions.
  • Guillain-Barré Syndrome (GBS): GBS is a rare neurological disorder. While a causal link between GBS and seasonal influenza vaccines is inconclusive, if an excess risk exists, it is very small. Individuals with a history of GBS within 6 weeks of a previous flu vaccination should discuss the risks and benefits with their doctor.
  • Febrile Seizures: Seizures related to fever can occur, especially in young children prone to them, although they are generally benign.
  • Syncope (Fainting): Can occur immediately after an injection, often as a psychogenic response to the needle.
  • Neurological disorders: Very rarely, conditions like encephalomyelitis, transverse myelitis, or brachial neuritis have been reported.
• Report any persistent, severe, or unusual side effects to a healthcare provider.

Several important warnings and precautions were associated with the administration of Fluzone PF Pediatric Quadrivalent 2021-2022 to ensure patient safety.

• Allergic Reactions: Do not administer to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine. Healthcare providers should have appropriate medical treatment readily available to manage severe allergic reactions.
• Guillain-Barré Syndrome (GBS): Individuals who have experienced GBS within 6 weeks following a previous influenza vaccination should have the decision to vaccinate based on careful consideration of potential benefits and risks.
• Altered Immunocompetence: Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a lower immune response to the vaccine.
• Acute Illness: Vaccination should be postponed in individuals with an acute illness accompanied by a moderate or high fever. A minor illness (e.g., common cold) without fever is usually not a reason to postpone vaccination.
• Limitations of Vaccine Effectiveness: No vaccine is 100% effective. Vaccination may not protect all recipients, particularly if the circulating strains do not closely match those in the vaccine.
• Egg Allergy: Current guidelines from public health authorities (including the CDC for the 2021-2022 season) stated that persons with egg allergy of any severity may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status. However, those with a history of severe allergic reaction to egg (e.g., angioedema, respiratory distress) should be vaccinated in a medical setting supervised by a healthcare provider able to manage severe allergic reactions.

• Vaccines typically have fewer drug-drug interactions compared to systemic medications. However:
  • Immunosuppressive Therapy: If administered to immunocompromised persons (e.g., those receiving high-dose corticosteroids, chemotherapy), the immune response to the vaccine may be lower than expected, potentially leading to reduced protection.
  • Other Vaccines: Fluzone PF Pediatric Quadrivalent could generally be co-administered with other age-appropriate vaccines on the same day, but it was important to administer them at different injection sites. Healthcare providers should always refer to current immunization schedules and guidelines for co-administration.

The dosage guidelines for Fluzone PF Pediatric Quadrivalent 2021-2022 were specific to the child’s age and previous flu vaccination history, aiming to ensure an adequate immune response.

• Children 6 months through 35 months:
  • If never vaccinated with flu vaccine before, or if vaccination history is unknown: Two doses of 0.25 mL or 0.5 mL, given at least 4 weeks apart.
  • If previously vaccinated with flu vaccine: One or two doses of 0.25 mL or 0.5 mL. The need for a second dose depended on the ACIP recommendations for that season and the number of doses the child received in previous flu seasons.
• Children 36 months through 8 years:
  • If never vaccinated with flu vaccine before, or if vaccination history is unknown: Two doses of 0.5 mL, given at least 4 weeks apart.
  • If previously vaccinated with flu vaccine: One or two 0.5 mL doses. Again, the need for a second dose depended on ACIP guidance and prior vaccination history.
• Children 9 years and older: One 0.5 mL dose.
• Administration Notes:
  • It was critical to administer the correct dose volume (0.25 mL or 0.5 mL) as per the age group and historical guidelines.
  • The vaccine was administered intramuscularly into the appropriate muscle (thigh for younger infants, deltoid for older children).
  • Vaccination was recommended annually, ideally before the peak of influenza activity in the community, typically in the fall.

Fluzone PF Pediatric Quadrivalent 2021-2022 was a prescription-only biological product (vaccine). It was administered by qualified healthcare professionals and was not available for self-administration.

• Medical Oversight: The administration of Fluzone PF Pediatric Quadrivalent required oversight by a licensed healthcare provider (physician, nurse, pharmacist, etc.) due to the need for proper injection technique, monitoring for immediate adverse reactions, and adherence to vaccination guidelines specific to pediatric populations.
• Not an OTC Product: Vaccines are not over-the-counter medications and require involvement of the healthcare system for proper screening, administration, and record-keeping.
• Public Health Programs: In many regions, pediatric influenza vaccination is integrated into public health immunization programs, making it accessible through pediatricians’ offices, clinics, or schools.
• Record Keeping: Healthcare providers maintained detailed records of vaccination, including the vaccine type, lot number, administration date, and the person who administered it, for public health tracking and patient safety.
• Annual Recommendation: The recommendation for vaccination with specific influenza vaccine products (including pediatric formulations) was issued annually by public health authorities (e.g., CDC in the US, national immunization committees elsewhere) based on epidemiologic data and vaccine effectiveness studies.

1. What is this vaccine used for? To prevent seasonal influenza in children aged 6–35 months.

2. What type of vaccine is it? Inactivated influenza virus vaccine (quadrivalent, preservative-free).

3. What strains are included in the 2021–2022 version? Two influenza A strains and two influenza B strains selected by WHO for that season.

4. What age group is it approved for? Children aged 6 months to 35 months.

5. What is the dosage and route? 0.25 mL intramuscular injection, typically in the thigh or deltoid muscle.

6. Is it a live vaccine? No, it is an inactivated (non-live) vaccine.

7. What are common side effects? Irritability, fever, injection site redness or swelling, and sleepiness.

8. Can it cause serious reactions? Rarely—allergic reactions, high fever, or seizures (febrile).

9. Is it safe during pregnancy? Not applicable; intended for pediatric use.

10. Is a prescription required? Yes, administered by healthcare professionals.

11. Is it available in Pakistan? Availability may vary; check with pediatric clinics or immunization centers.

12. Can it be used with other pediatric vaccines? Yes, often co-administered with routine childhood immunizations.

13. How long does protection last? Typically 6–12 months; annual vaccination is recommended.

14. What makes it different from adult Fluzone? Lower volume (0.25 mL) and tailored for infants and toddlers.

15. Is it used for COVID-19 prevention? No, it only protects against influenza.

16. Can it be used in immunocompromised children? Yes, but consult a pediatrician.

17. What should be avoided after vaccination? Monitor for fever or allergic reactions; no specific activity restrictions.

18. Is it part of routine immunization? Yes, during flu season for eligible age groups.

19. What does “PF” mean? Preservative-free formulation.

20. Is a booster dose needed? Yes—children receiving flu vaccine for the first time need two doses at least 4 weeks apart.